Organogenesis (ORGO) vs Sofgen Pharma S.A (PROCF)
- Organogenesis ORGO 0.99 −10.81%
- Sofgen Pharma S.A PROCF 0.03 0.00%
Organogenesis and Sofgen Pharma S.A are both Drug Manufacturers Specialty & Generic companies. Organogenesis is the larger, with a market value of $142.8M against $114.0M — 1.3× the size. Organogenesis has negative trailing earnings, so its P/E is not meaningful; Sofgen Pharma S.A trades at 0.1×. Organogenesis grew revenue faster over the last twelve months: 6.50% against 5.10%. Sofgen Pharma S.A has the higher net margin (9.52% vs −22.2%) and the higher return on invested capital (15.2% vs −20.0%). Across the 19 metrics below, Sofgen Pharma S.A leads on 11 and Organogenesis on 8.
Valuation
Profitability
| Metric | ORGO | PROCF | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 70.35% | 56.16% | 53.94% |
| Operating margin | (7.84%) | 17.01% | 0.00% |
| Net margin | (22.23%) | 9.52% | 0.00% |
| Free cash flow margin | 4.56% | 17.66% | 0.00% |
| Return on equity | (53.31%) | (213.06%) | (0.40%) |
| Return on assets | (23.44%) | 8.82% | (3.32%) |
| Return on invested capital | (19.97%) | 15.21% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack